Clarisol-500 Uses

• Clarisol-500 indications
• Uses of Clarisol-500 in details
• Clarisol-500 description
• Clarisol-500 dosage
• Clarisol-500 interactions
• Clarisol-500 side effects
• Clarisol-500 contraindications

What is Clarisol-500?

Clarisol-500 is used to treat bacterial infections in many different parts of the body. It is also used in combination with other medicines to treat duodenal ulcers caused by H. pylori. Clarisol-500 is also used to prevent and treat Mycobacterium avium complex (MAC) infection.

Clarisol-500 belongs to the class of medicines known as macrolide antibiotics. It works by killing bacteria or preventing their growth. However, Clarisol-500 will not work for colds, flu, or other virus infections.

Clarisol-500 is available only with your doctor's prescription.

Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although this use is not included in product labeling, Clarisol-500 is used in certain patients with the following medical condition:

• Legionnaires' disease.

Clarisol-500 indications

Acute Bacterial Exacerbation of Chronic Bronchitis

Clarisol-500 tablets, Clarisol-500 for oral suspension and Clarisol-500 extended-release tablets are indicated in adults for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.

Acute Maxillary Sinusitis

Clarisol-500 tablets, Clarisol-500 for oral suspension and Clarisol-500 extended-release tablets (in adults) are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.

Community-Acquired Pneumonia

Clarisol-500 tablets, Clarisol-500 for oral suspension and Clarisol-500 extended-release tablets are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to:

• Haemophilus influenzae (in adults)
• Haemophilus parainfluenzae (Clarisol-500 extended-release tablets in adults)
• Moraxella catarrhalis (Clarisol-500 extended-release tablets in adults)
• Mycoplasma pneumoniae, Streptococcus pneumoniae, Chlamydophila pneumoniae (Clarisol-500 extended-release tablets [in adults]; Clarisol-500 tablets and Clarisol-500 for oral suspension [in adults and pediatric patients])

Pharyngitis/Tonsillitis

Clarisol-500 tablets and Clarisol-500 for oral suspension are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Streptococcus pyogenes as an alternative in individuals who cannot use first line therapy.

Uncomplicated Skin and Skin Structure Infections

Clarisol-500 tablets and Clarisol-500 for oral suspension are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Staphylococcus aureus, or Streptococcus pyogenes.

Acute Otitis Media

Clarisol-500 tablets and Clarisol-500 for oral suspension are indicated in pediatric patients for the treatment of mild to moderate infections caused by susceptible isolates due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.

Treatment and Prophylaxis of Disseminated Mycobacterial Infections

Clarisol-500 tablets and Clarisol-500 for oral suspension are indicated for the treatment of mild to moderate infections caused by susceptible isolates due to Mycobacterium avium or Mycobacterium intracellulare in patients with advanced HIV infection.

Helicobacter pylori Infection and Duodenal Ulcer Disease

Clarisol-500 tablets are given in combination with other drugs in adults as described below to eradicate H. pylori. The eradication of H. pylori has been demonstrated to reduce the risk of duodenal ulcer recurrence.

• Clarisol-500 tablets in combination with amoxicillin and PREVACID (lansoprazole) or PRILOSEC (omeprazole) delayed-release capsules, as triple therapy, are indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or five-year history of duodenal ulcer) to eradicate H. pylori.
• Clarisol-500 tablets in combination with PRILOSEC (omeprazole) capsules are indicated for the treatment of patients with an active duodenal ulcer associated with H. pylori infection. Regimens which contain Clarisol-500 tablets as the single antibacterial agent are more likely to be associated with the development of Clarisol-500 resistance among patients who fail therapy. Clarisol-500-containing regimens should not be used in patients with known or suspected Clarisol-500 resistant isolates because the efficacy of treatment is reduced in this setting.

Limitations of Use

Clarisol-500 extended-release tablets are indicated only for acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, and community-acquired pneumonia in adults. The efficacy and safety of Clarisol-500 extended-release tablets in treating other infections for which Clarisol-500 tablets and Clarisol-500 for oral suspension are approved have not been established.

There is resistance to macrolides in certain bacterial infections caused by Streptococcus pneumoniae and Staphylococcus aureus. Susceptibility testing should be performed when clinically indicated.

Usage

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Clarisol-500 and other antibacterial drugs, Clarisol-500 should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

How should I use Clarisol-500?

Use Clarisol-500 extended-release tablets as directed by your doctor. Check the label on the medicine for exact dosing instructions.

• Take Clarisol-500 extended-release tablets by mouth with food.
• Swallow Clarisol-500 extended-release tablets whole. Do not break, crush, or chew before swallowing.
• If you are also taking zidovudine, do not take it within 2 hours before or after Clarisol-500 extended-release tablets.
• Clarisol-500 extended-release tablets works best if it is taken at the same time each day.
• To clear up your infection completely, take Clarisol-500 extended-release tablets for the full course of treatment. Keep taking it even if you feel better in a few days.
• Do not miss any doses. If you miss a dose of Clarisol-500 extended-release tablets, take it as soon as possible. If it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not take 2 doses at once.

Ask your health care provider any questions you may have about how to use Clarisol-500 extended-release tablets.

Uses of Clarisol-500 in details

Use: Labeled Indications

Chronic obstructive pulmonary disease, acute exacerbation: Treatment of acute bacterial exacerbation of chronic bronchitis in adults due to susceptible Haemophilus influenzae, Haemophilus parainfluenzae, Moraxella catarrhalis, or Streptococcus pneumoniae.

Helicobacter pylori eradication: Eradication of Helicobacter pylori to reduce the risk of duodenal ulcer recurrence as a component of combination therapy (triple therapy) in adults with H. pylori infection and duodenal ulcer disease (active or 5-year history of duodenal ulcer).

Limitations of use: Regimens that contain Clarisol-500 as the single antibacterial agent are more likely to be associated with the development of Clarisol-500 resistance. Clarisol-500-containing regimens should not be used in patients with known or suspected Clarisol-500-resistant isolates (efficacy is reduced).

Mycobacterial (nontuberculous) infection: Prophylaxis and treatment of disseminated mycobacterial infections due to Mycobacterium avium complex (MAC) in patients with advanced HIV infection.

Otitis media: Treatment of acute otitis media in pediatric patients due to susceptible H. influenzae, M. catarrhalis, or S. pneumoniae.

Pneumonia, community-acquired: Treatment of community-acquired pneumonia due to susceptible Mycoplasma pneumoniae, S. pneumoniae, or Chlamydophila pneumoniae (adult and pediatric patients) and H. influenzae, H. parainfluenzae, or M. catarrhalis (adults).

Skin/skin structure infection: Treatment of uncomplicated skin/skin structure infection due to susceptible Staphylococcus aureus or Streptococcus pyogenes.

Streptococcal pharyngitis: Treatment of pharyngitis/tonsillitis due to susceptible S. pyogenes (alternative agent for patients with severe penicillin allergy).

Off Label Uses

Bartonella spp. infection

Based on the US Department of Health and Human Services guidelines for prevention and treatment of opportunistic infections in adults and adolescents with HIV, Clarisol-500 is an effective and recommended alternative agent for treatment or long-term suppression of bartonellosis infection.

Clinical experience also suggests the utility of Clarisol-500 for the treatment of cat scratch disease.

Clarisol-500 description

Clarisol-500: Clarisol-500 250 mg, Immediate-Release Tablet: One tablet contains 250mg Clarisol-500. Tablet sodium content: 3.4 mg tablet.

Clarisol-500 Forte: Clarisol-500 500 mg, Immediate-Release Tablet: One tablet contains 500mg Clarisol-500. Tablet sodium content: 6.1 mg tablet.

Clarisol-500 MR: Clarisol-500 500 mg, Modified-Release Tablet: One tablet contains 500 mg Clarisol-500.

Clarisol-500 Paediatric Suspension 125 mg/5 mL: Clarisol-500 125 mg/5 ml, Granules for

Oral Suspension (Pediatric Suspension): Each 5 ml of the granules for suspension contains 125 mg of Clarisol-500.

Clarisol-500 Paediatric Suspension 250 mg/5 mL: Clarisol-500 250 mg/5 ml, Granules for

Oral Suspension (Pediatric Suspension): Each 5 ml of the granules for suspension contains 250 mg of Clarisol-500.

Clarisol-500 is a semisynthetic macrolide antibiotic obtained by substitution of a CH₃O group for the hydroxyl (OH) group in position 6 of the erythromycin lactonic ring. Specifically, Clarisol-500 is 6-O-methyl erythromycin A. The white to off-white antibiotic powder is practically odorless, essentially insoluble in water and slightly soluble in ethanol, methanol and acetonitrile. Its molecular weight is 747.96.

Clarisol-500 Paediatric Suspension is an oral dosage form of Clarisol-500 for use primarily in children.

Excipients/Inactive Ingredients: Clarisol-500: Tablet Core: Croscarmellose sodium, pregelatinized starch, microcrystalline cellulose, quinoline yellow (E104 aluminium lake), silicon dioxide, povidone, stearic acid, magnesium stearate, talc. Tablet Coating, Colour and Gloss Coating: Hypromellose, sorbitan monooleate, propylene glycol, titanium dioxide, vanillin, quinoline yellow (E104 aluminium lake), hydroxypropyl cellulose, sorbic acid.

Clarisol-500 Forte: Tablet Core: Croscarmellose sodium, microcrystalline cellulose, silicon dioxide, povidone, stearic acid, magnesium stearate, talc. Tablet Coating, Colour and Gloss Coating: Hypromellose, sorbitan monooleate, propylene glycol, titanium dioxide, vanillin, quinoline yellow (E104 aluminium lake), hydroxypropyl cellulose, sorbic acid.

Clarisol-500 MR: Tablet Core: Citric acid, sodium alginate, sodium calcium alginate, lactose, povidone, talc, stearic acid, magnesium stearate. Coating Solution: Hypromellose, polyethylene glycol, titanium dioxide, quinoline yellow (E104 aluminium lake), sorbic acid.

Clarisol-500 Paediatric Suspension: Granule Component and Coating: Carbopol carbomers, povidone, hypromellose phthalate, castor oil. Other Ingredients: Sucrose, xanthan gum, silicon dioxide, potassium sorbate, citric acid, maltodextrin, titanium dioxide, fruit punch flavor.

Clarisol-500 dosage

Clarisol-500/Clarisol-500 Forte: Respiratory Tract/Skin and Soft Tissue Infections: Adults and Children ≥12 years: Usual Dose: 250 mg twice daily for 7 days, although this may be increased to 500 mg twice daily for up to 14 days in severe infections.

Children <12 years: Use Clarisol-500 Paediatric Suspension. The use of Clarisol-500 IR has not been studied in children <12 years.

Eradication of H. pylori: Adults and Elderly Triple Therapy Regimen: Clarisol-500 500 mg twice daily in conjunction with amoxicillin 1000 mg twice daily and a proton-pump inhibitor in standard dose twice daily for 7 days.

Dual Therapy Regimen: Clarisol-500 500 mg 3 times daily in conjunction with omeprazole 40 mg once daily for 14 days, followed by omeprazole 40 mg once daily for an additional 14 days. Supportive studies have been conducted with omeprazole 40 mg once daily for 14 days.

Renal Impairment: Dosage adjustments are not usually required except in patients with severe renal impairment (creatinine clearance <30 mL/min). If adjustment is necessary, the total daily dosage should be reduced by ½ eg, 250 mg once daily or 250 mg twice daily in more severe infections.

Clarisol-500 may be given without regard to meals as food does not affect the extent of bioavailability.

Clarisol-500 MR: Adults and Children >12 years: Usual Recommended

Dosage: 1 modified-release tab daily to be taken with food. In more severe infections, the dosage can be increased to 2 tabs daily. The usual duration of treatment is 7-14 days.

Children <12 years: Use Clarisol-500 Paediatric Suspension. The use of Clarisol-500 MR has not been studied in children <12 years.

Renal Impairment: Clarisol-500 MR should not be used in patients with renal impairment (creatinine clearance <30 mL/min). Clarisol-500 immediate-release tablets may be used in this patient population.

Do not crush or chew Clarisol-500 MR tablets.

Clarisol-500 Paediatric Suspension: Children 6 months to 12 years: Clinical trials have been conducted using Clarisol-500 Pediatric Suspension in children 6 months-12 years. Therefore, children 6 months-12 years of age should use Clarisol-500 Pediatric Suspension (granules for oral suspension).

Recommended Daily

Dosage: 7.5 mg/kg twice daily up to a maximum dose of 500 mg twice daily for nonmycobacterial infections. The usual duration of treatment is for 5-10 days depending on the pathogen involved and the severity of the condition. The prepared suspension can be taken with or without meals, and can be taken with milk.

Table 3 is a suggested guide for determining

Dosage: See Table 3.

Patients with Renal Impairment: In children with creatinine clearance <30 mL/min, the dosage of Clarisol-500 should be reduced by ½ ie, up to 250 mg once daily or 250 mg twice daily in more severe infections. Dosage should not be continued >14 days in these patients.

Patients with Mycobacterial Infections: In children with disseminated or localized mycobacterial infections (M. avium, M. intracellulare, M. chelonae, M. fortuitum, M. kansasii), the recommended dose is 15-30 mg/kg/day in 2 divided doses.

Treatment with Clarisol-500 should continue as long as clinical benefit is demonstrated. The addition of other antimycobacterial agents may be of benefit.

Clarisol-500 interactions

See also:
What other drugs will affect Clarisol-500?

Clarisol-500: Data available to date indicate that Clarisol-500 is metabolized primarily by the hepatic cytochrome P-450 3A (CYP3A) isozyme. This is an important mechanism determining many drug interactions.

The metabolism of other drugs by this system may be inhibited by concomitant administration with Clarisol-500 and may be associated with elevations in serum levels of drug classes known or suspected to be metabolized by the same CYP450 and CYP3A isozyme.

Other Drug Interactions: Elevated digoxin serum concentrations have been reported in patients receiving Clarisol-500 tablets and digoxin concomitantly. Monitoring of serum digoxin levels should be considered.

There have been post-marketing reports of Torsades de pointes occurring with concurrent use of Clarisol-500 and quinidine or disopyramide. Serum levels of these medications should be monitored during Clarisol-500 therapy.

Rhabdomyolysis coincident with the co-administration of Clarisol-500 and the HMG-CoA reductase inhibitors eg, lovastatin and simvastatin has rarely been reported.

Antiretroviral Drug Interactions: Simultaneous oral administration of Clarisol-500 tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. Because Clarisol-500 appears to interfere with the absorption of simultaneously administered oral zidovudine, this interaction can be largely avoided by staggering the doses of Clarisol-500 and zidovudine. This interaction does not appear to occur in pediatric HIV-infected patients taking Clarisol-500 suspension with zidovudine or dideoxyinosine.

A pharmacokinetic study demonstrated that the concomitant administration of ritonavir 200 mg every 8 hrs and Clarisol-500 500 mg every 12 hrs resulted in a marked inhibition of the metabolism of Clarisol-500.

For patients with renal impairment, the following dosage adjustments should be considered: For patients with CrCl 30-60 mL/min, the dose of Clarisol-500 should be reduced by 50%. For patients with CrCl <30 mL, the dose of Clarisol-500 should be decreased by 75%. Doses of Clarisol-500 >1 g/day should not be co-administered with ritonavir.

Clarisol-500 OD: As with other macrolide antibiotics, the use of Clarisol-500 in patients concurrently taking drugs metabolized by the cytochrome P-450 system (eg, cilostazol, methylprednisolone, anticoagulants eg, warfarin, quinidine, sildenafil, ergot alkaloids, alprazolam, triazolam, midazolam, disopyramide, lovastatin, rifabutin, phenytoin, cyclosporin, vinblastine, valproate and tacrolimus) may be associated with elevations in serum levels of these other drugs.

Digoxin: Elevated digoxin serum concentrations have been reported in patients receiving Clarisol-500 tablets and digoxin concomitantly. Monitoring of serum digoxin levels should be considered.

Quinidine/Disopyramide: There have been post-marketed reports of Torsades de pointes occurring with concurrent use of Clarisol-500 and quinidine or disopyramide. Electrocardiogram and serum levels of these medications should be monitored during Clarisol-500 therapy.

HMG-CoA Reductase Inhibitors: As with other macrolides, Clarisol-500 has been reported to increase concentrations of HMG-CoA reductase inhibitors (eg, statins). Rhabdomyolysis has also been reported in patients taking these drugs concomitantly.

Theophylline, Carbamazepine: The administration of Clarisol-500 to patients receiving theophylline or carbamazepine has been associated with an increase in serum theophylline or carbamazepine levels.

Oral Anticoagulants:

Concomitant administration of Clarisol-500 and oral anticoagulants may potentiate the effects of oral anticoagulants. Prothrombin time should be carefully monitored while patients are receiving Clarisol-500 and oral anticoagulants simultaneously.

Ritonavir: Ritonavir increases AUC, C_max and C_min of Clarisol-500 when administered concurrently. Because of the large therapeutic window for Clarisol-500, no dosage reduction should be necessary in patients with normal renal function. However, for patients with renal impairment, the following dosage adjustments should be considered: For patients with CrCl 30-60 mL/min, the dose of Clarisol-500 should be reduced by 50%. For patients with CrCl <30 mL/min, the dose of Clarisol-500 should be decreased by 75%. Doses of Clarisol-500 >1 g/day should not be co-administered with ritonavir.

Efavirenz, Nevirapine, Rifampicin and Rifabutin: Strong inducers of the cytochrome P-450 metabolism system eg, efavirenz, nevirapine, rifampicin and rifabutin may accelerate the metabolism of Clarisol-500 and thus, lower the plasma levels of Clarisol-500. Since the microbiological activities of Clarisol-500 and 14-OH-Clarisol-500 are different for different bacteria, the intended therapeutic effect could be impaired during concomitant administration of Clarisol-500 and enzyme inducers.

Sildenafil, Tadalafil and Vardenafil: Each of these phosphodiesterase inhibitors is metabolized, at least in part, by CYP3A, and CYP3A may be inhibited by concomitantly administered Clarisol-500. Reduction in sildenafil, tadalafil and vardenafil dosages should be considered when these drugs are co-administered with Clarisol-500.

Triazolam: Drug interactions and CNS effects (eg, somnolence and confusion) with the concomitant use of Clarisol-500 and triazolam have been reported. Monitoring the patient for increased CNS pharmacological effects is suggested.

Colchicine: When Clarisol-500 and colchicine are administered together, inhibition of Pgp and/or CYP3A by Clarisol-500 may lead to increased exposure to colchicine. Patients should be monitored for clinical symptoms of colchicine toxicity.

Itraconazole: Both Clarisol-500 and itraconazole are substrates and inhibitors of CYP3A. Clarisol-500 may increase the plasma levels of itraconazole, while itraconazole may increase the plasma levels of Clarisol-500. Patients taking itraconazole and Clarisol-500 concomitantly should be monitored closely for signs and symptoms of increased or prolonged pharmacological effect.

Zidovudine: Simultaneous oral administration of Clarisol-500 tablets and zidovudine to HIV-infected adult patients may result in decreased steady-state zidovudine concentrations. This interaction does not appear to occur in pediatric HIV-infected patients taking Clarisol-500 suspension with zidovudine or dideoxyinosine.

Clarisol-500 side effects

See also:
What are the possible side effects of Clarisol-500?

The most frequent and common adverse reactions related to Clarisol-500 therapy for both adult and pediatric populations are abdominal pain, diarrhea, nausea, vomiting and taste perversion. These adverse reactions are usually mild in intensity and are consistent with the known safety profile of macrolide antibiotics.

There was no significant difference in the incidence of these gastrointestinal adverse reactions during clinical trials between the patient population with or without preexisting mycobacterial infections.

The following table displays adverse reactions reported in clinical trials and from post-marketing experience with Clarisol-500 immediate release, granules for oral suspension, IV and MR.

The reactions considered at least possibly related to Clarisol-500 are displayed by system organ class and frequency using the following convention: Very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1000 to <1/100) and not known (adverse reactions from post-marketing experience; cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness when the seriousness could be assessed.

There have been post-marketing reports of colchicine toxicity with concomitant use of Clarisol-500 and colchicine, especially in the elderly, some of which occurred in patients with renal insufficiency. Deaths have been reported in some such patients.

Immunocompromised Patients: In AIDS and other immunocompromised patients treated with the higher doses of Clarisol-500 over long periods of time for mycobacterial infections, it was often difficult to distinguish adverse events possibly associated with Clarisol-500 administration from underlying signs of HIV disease or intercurrent illness.

Clarisol-500/Clarisol-500 Forte: In adult patients, the most frequently reported adverse events by patients treated with total daily doses of Clarisol-500 1000 mg were: Nausea, vomiting, taste perversion, abdominal pain, diarrhea, rash, flatulence, headache, constipation, hearing disturbance, SGOT and SGPT elevations. Additional low-frequency events included dyspnea, insomnia and dry mouth.

In these immunocompromised patients evaluations of laboratory values were made by analyzing those values outside the seriously abnormal level (ie, the extreme high or low limit) for the specified test. On the basis of this criteria, about 2-3% of these patients who received Clarisol-500 1000 mg daily had seriously abnormal elevated levels of SGOT and SGPT, and abnormally low white blood cell and platelet counts. A lower percentage of patients also had elevated BUN levels.

Clarisol-500 Paediatric Suspension: A limited number of pediatric AIDS patients have been treated with Clarisol-500 Pediatric Suspension for mycobacterial infections. The most frequently reported adverse events, excluding those due to the patient's concurrent condition, were tinnitus, deafness, vomiting, nausea, abdominal pain, purpuric rash, pancreatitis and increased amylase. Evaluations of laboratory values for these patients were made by analyzing those values outside the seriously abnormal level (ie, the extreme high or low limit) for the specified test. Based on these criteria, 1 pediatric AIDS patient receiving <15 mg/kg/day of Clarisol-500 had a seriously abnormal (elevated) total bilirubin; of the patients receiving 15 to <25 mg/kg/day of Clarisol-500, there was 1 each reported as seriously abnormal SGPT, BUN, and seriously decreased platelet count. None of these seriously abnormal values for these laboratory parameters were reported for patients receiving the highest dosage (≤25 mg/kg/day) of Clarisol-500.

Clarisol-500 contraindications

See also:
What is the most important information I should know about Clarisol-500?

Clarisol-500 is contraindicated in patients with a known hypersensitivity to Clarisol-500 or any of its excipients, erythromycin, or any of the macrolide antibiotics.

Clarisol-500 is contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of Clarisol-500.

Concomitant administration of Clarisol-500 and any of the following drugs is contraindicated: cisapride, pimozide, astemizole, terfenadine and ergotamine or dihydroergotamine. There have been post-marketing reports of drug interactions when Clarisol-500 and/or erythromycin are coadministered with cisapride, pimozide, astemizole, or terfenadine resulting in cardiac arrhythmias (QT prolongation, ventricular tachycardia, ventricular fibrillation, and torsades de pointes) most likely due to inhibition of metabolism of these drugs by erythromycin and Clarisol-500. Fatalities have been reported.

Concomitant administration of Clarisol-500 and colchicine is contraindicated in patients with renal or hepatic impairment.

Clarisol-500 should not be given to patients with history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes.

Clarisol-500 should not be used concomitantly with HMG-CoA reductase inhibitors (statins) that are extensively metabolized by CYP3A4 (lovastatin or simvastatin), due to the increased risk of myopathy, including rhabdomyolysis.

For information about contraindications of other drugs indicated in combination with Clarisol-500, refer to the CONTRAINDICATIONS section of their package inserts.

Active ingredient matches for Clarisol-500:

Clarithromycin in Vietnam.

Unit description / dosage (Manufacturer)	Price, USD
Clarisol-500 500 mg x 1 Blister x 10 Tablet
List of Clarisol-500 substitutes (brand and generic names):
Clarisdase TAB
Clarisdase TAB Clarithromycin 250mg, Serratiopeptidase 10mg TAB / 10	$ 3.70
Clarison (Bangladesh)
Clarista (Pakistan)
CLARISTAR (India)
CLARISTAR tab 250 mg x 4's (Invision)
CLARISTAR tab 500 mg x 4's (Invision)
Clariston (Ecuador)
Clarit
Clarit 250 mg Tablet (Finecure Pharmaceuticals Ltd)	$ 0.14
Clarit 30 ml Syrup (Finecure Pharmaceuticals Ltd)	$ 0.09
Clarit DT
Clarit DT 125 mg Tablet (Finecure Pharmaceuticals Ltd)	$ 0.13
Claritab (Vietnam)
Claritab 250 mg x 4 Blister x 5 Tablet (Ache)
Claritab 500 mg x 4 Blister x 5 Tablet (Ache)
CLARITAL
CLARITAL 250MG TABLET 1 strip / 10 tablets each (Talent Healthcare)	$ 2.03
Claritee (India)
Claritee 125mg DRY-SYR / 30ml (Innokon)	$ 1.20
Claritee 250mg TAB / 4 (Innokon)	$ 1.25
Claritee 500mg TAB / 4 (Innokon)	$ 2.36
CLARITEE tab 250 mg x 4's (Innokon)	$ 1.25
CLARITEE tab 500 mg x 4's (Innokon)	$ 2.36
CLARITEE dry syr 125 mg x 30ml (Innokon)	$ 1.20
Claritek (Vietnam)
Claritek 250 mg x 1 Blister 10 Tablet
Claritek 500 mg x 1 Blister 10 Tablet
Claritek 125 mg/5 mL x 1 Bottle 25 mL
Claritek 125 mg/5 mL x 1 Bottle 50 mL
Clarith (Japan, South Korea, Thailand)
Clarith 500 mg x 14's (L. B. S.)
250 mg x 10's (L. B. S.)
500 mg x 10's (L. B. S.)
Clarith 250mg TAB / 10 (L. B. S.)
Clarith 500mg TAB / 10 (L. B. S.)
Clarith film-coated tab 500 mg 14's (L. B. S.)
CLARITH tab 250 mg x 10's (L. B. S.)
CLARITH tab 500 mg x 10's (L. B. S.)
Clarith 10% (Japan)
Clarithin (South Korea)
Clarithomycin
Clarithomycin 250mg (Vietnam)
Clarithomycin 250mg 250 mg x 1 Blister x 10 Tablet
Clarithomycin 250mg 250 mg x 2 Blister x 10 Tablet
CLARITHRAL (India)
CLARITHRAL tab 250 mg x 10's (Innovative)	$ 3.49
CLARITHRAL oral susp 125 mg x 5 mL x 30ml (Innovative)	$ 1.39
Clarithro (Australia, Ethiopia, India, Tunisia)
Tablet, Film-Coated; Oral; Clarithromycin 250 mg (Alembic Chemical Works Co Ltd)
CLARITHRO Capsule/ Tablet / 250mg / 4 units (Alembic Chemical Works Co Ltd)	$ 0.96
CLARITHRO Capsule/ Tablet / 500mg / 4 units (Alembic Chemical Works Co Ltd)	$ 1.65
Clarithro 250mg FC-TAB / 4 (Alembic Chemical Works Co Ltd)	$ 0.96
Clarithro 500mg FC-TAB / 4 (Alembic Chemical Works Co Ltd)	$ 1.81
See 2404 substitutes for Clarisol-500

References

1. DailyMed. "CLARITHROMYCIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
2. PubChem. "clarithromycin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
3. DrugBank. "clarithromycin". http://www.drugbank.ca/drugs/DB01211 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Clarisol-500 are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Clarisol-500. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reviews

There are no reviews yet. Be the first to write one!

Your name:  Email:  Spam protection:  < Type 26 here

Information checked by Dr. Sachin Kumar, MD Pharmacology